PARP inhibitors in gastric cancer: beacon of hope
| Autor: | Rui Chen, Kun Zheng, Jinfang Su, Yongbiao Huang, Hua Xiong, Yali Wang, Yanmei Zou |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Genome instability Cancer Research DNA damage DNA repair Poly ADP ribose polymerase Review Poly(ADP-ribose) Polymerase Inhibitors DNA damage response 03 medical and health sciences 0302 clinical medicine Transcription (biology) Stomach Neoplasms medicine Humans Homologous Recombination Polymerase RC254-282 biology Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology PARP inhibitor Oncology 030220 oncology & carcinogenesis Cancer treatment Cancer research biology.protein Gastric cancer Signal Transduction |
| Zdroj: | Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021) Journal of Experimental & Clinical Cancer Research : CR |
| ISSN: | 1756-9966 |
| Popis: | Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to cell death when they inhibit DNA damage repair. Poly (ADP-ribose) polymerase (PARP) plays a central role in many cellular processes, including DNA repair, replication, and transcription. PARP induces the occurrence of poly (ADP-ribosylation) (PARylation) when DNA single strand breaks (SSB) occur. PARP and various proteins can interact directly or indirectly through PARylation to regulate DNA repair. Inhibitors that directly target PARP have been found to block the SSB repair pathway, triggering homologous recombination deficiency (HRD) cancers to form synthetic lethal concepts that represent an anticancer strategy. It has therefore been investigated in many cancer types for more effective anti-cancer strategies, including gastric cancer (GC). This review describes the antitumor mechanisms of PARP inhibitors (PARPis), and the preclinical and clinical progress of PARPis as monotherapy and combination therapy in GC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|